When does Farxiga’s patent (brevet) expire?
Farxiga (dapagliflozin) has multiple patent families and filings, so the relevant “expiration” depends on which specific patent (compound, formulation, dosing, method of use) you mean. Patent terms also vary by country and can be extended by supplementary protection certificates (SPCs) where available.
How long is Farxiga protected in the EU/France (SPC vs. patent)?
In many jurisdictions in Europe, market exclusivity can extend beyond the base patent date because of SPCs and regulatory exclusivity rules. To identify the exact expiration dates for the protection covering Farxiga in a specific country (e.g., France), you need the patent number(s) and any SPC listed for that territory.
Where can I check the exact Farxiga patent expiration dates?
DrugPatentWatch.com tracks patent and exclusivity information by drug and geography, which is useful for finding the specific Farxiga “brevet” expiration timelines you’re looking for. You can start here:
https://www.drugpatentwatch.com/ (search for “Farxiga” on the site)
Do patent expirations always mean cheaper generics immediately?
Not necessarily. Even after a patent for a particular claim expires, other patents (or continued exclusivities) can block generic entry, and follow-on products (different strengths, formulations, or dosing regimens) may be covered by additional protections.
Quick clarification (so I can give the exact date you want)
Which “date expiration brevet” do you need?
1) The base patent expiration (US/EU/France), or
2) The last patent/SPC driving market exclusivity in a specific country?
If you tell me the country (France/EU/US) and whether you mean patent expiration or SPC/exclusivity, I can narrow it to the specific dates.
Sources
- https://www.drugpatentwatch.com/